Relapsed/Refractory Multiple Myeloma: Incidence of CRS in MajesTEC-1
Focused discussion on the advent of cytokine release syndrome in MajesTEC-1 and how it compared to the benefits derived from teclistamab therapy.
Unmet Needs and Future Directions in the Management of Multiple Myeloma
Experts from Ochsner Health close out their panel on multiple myeloma management by identifying unmet needs and sharing excitement for future evolution in the treatment landscape.
Colorectal Cancer Treatment Considerations Following IDEA Collaboration Analysis
A comprehensive discussion on treatment decision-making for patients with colorectal cancer following the IDEA collaboration analysis.
What is the Role of Cytogenetics/Genomics in Myelofibrosis?
Shared insight from a panel of experts on the current state of cytogenetics in myelofibrosis and how it impacts treatment pathways for patients.
Identifying the Signs and Symptoms of Myelofibrosis
Expert panelists provide an overview of the signs and symptoms indicative of myelofibrosis and consider factors that help to inform prognostication.
First-Line Treatment Options for NPM1-mutant AML
Eunice S. Wang, MD, shares first-line treatment approaches for patients with NPM1-mutant AML, discussing current clinical data.
Treatment Options for a Young, Fit Patient Newly Diagnosed with AML
The panel discuss the need for personalized treatment approaches for young, fit patients with newly diagnosed acute myeloid leukemia, as well as when transplant should be considered.
Implementing Real-world Evidence into Clinical Practice in NDMM
Clinical pearls for community oncologists concerning the real-world application of existing treatments while considering feasibility, cost, and ease of care.
Assessing and Supporting Frail Patients with NDMM
Conversation centered around patient frailty, Dr. Cook and Dr. Pianko emphasize the importance of accurately assessing frailty and adjusting treatment plans accordingly.
Long-Term Followup With Talquetamab in Relapsed/Refractory MM: Infection Rates
Expert hematologist-oncologists identify long-term data from MonumenTAL-1 regarding infection rates in patients with relapsed/refractory multiple myeloma.
Practical Considerations for Talquetamab Use in Relapsed/Refractory Multiple Myeloma
Following their review of data from MonumenTAL-1, Ajai Chari, MD, and Carolina Schinke, MD, share practical considerations for real-world use of talquetamab in relapsed/refractory multiple myeloma.
Pembrolizumab Plus Axitinib Versus Sunitinib for First-Line Treatment of Advanced Clear Cell RCC
Brian Rini, MD, reviews data from the 5-year analysis of the KEYNOTE-426 trial in advanced clear cell renal cell carcinoma.
Lenvatinib Plus Pembrolizumab Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma (aRCC)
Robert Motzer, MD, presents the overall survival analysis data from the 4-year follow-up of the CLEAR study in patients with advanced renal cell carcinoma.
Diagnosis, Biomarker Testing, and Optimizing Treatment Selection for Patients with AML
Drs. Koprivnikar, McCloskey, and Cho delve into the diagnostic process in acute myeloid leukemia (AML), treatment approaches for AML, and factors influencing treatment selection.
Innovations in MPN Therapy: Ongoing Trials and Latest Findings
A closer look at the current unmet needs in MPN treatment, ongoing trials, and recent updates such as the MOMENTUM and FREEDOM trials.
Diagnosing Bladder Cancer: Best Practices in Workup and Staging
Shared insight on the standard work-up and staging practices used when a patient presents with newly diagnosed bladder cancer.
Patient Case Review: What is a Typical Presentation of Bladder Cancer?
Expert panelists review a patient presentation of bladder cancer and consider the typical signs and symptoms that may lead to a diagnosis.
Community Care Provider’s Perspective on Administering Bispecifics in Patients with MM
Focused discussion on how patients receiving bispecific therapy for multiple myeloma are transitioned into and managed within the community setting.
Bispecifics in Multiple Myeloma: Transitioning Patient Care to the Community Setting
Expert panelists share insight on transitioning patients on bispecific therapy from an academic or specialty center to the community setting.
The Future of Treatment for Patients with MDS
Dr. Daver anticipates how the MDS landscape will evolve over time, emphasizing the importance of adopting targeted therapies.
